TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33446307

Group type: EXPERIMENTAL
Intervention: Multivessel PCI (MV‐PCI)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Culprit lesion–only PCI (CLO‐PCI)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Residual SYNTAX score (rSS)
Number of subjects: 587
Study: 32442673

Group type: EXPERIMENTAL
Intervention: Oxytocin administration (24 IU intranasally)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 100
Study: 34382385

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 1142
Study: 34654385

Group type: EXPERIMENTAL
Intervention: Tailored education resource focusing on liver cancer prevention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard HBV education package
Number of subjects: 54
Study: 36319962

Group type: EXPERIMENTAL
Intervention: Peripatellar plexus block (PP group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Femoral nerve block (FN group)
Number of subjects: 50
Study: 33683465

Group type: EXPERIMENTAL
Intervention: High-viscosity glass ionomer (Hv-GIC)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nanohybrid resin composite
Number of subjects: 56
Study: 35193640

Group type: EXPERIMENTAL
Intervention: Biportal endoscopic discectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Microscopic discectomy
Number of subjects: 100
Study: 34776475

Group type: EXPERIMENTAL
Intervention: Horseshoe osteotomy (HS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: LeFort I osteotomy (LF)
Number of subjects: 40
Study: 35473589

Group type: EXPERIMENTAL
Intervention: COPD prediction algorithm integrated into telehealth system
Number of subjects: 200
Study: 34369696

Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiting (ST 44), Xiangu (ST 43), Dadu (SP 2), Taibai (SP 3), Zusanli (ST 36), etc. once every other day, 3 times a week for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic treatment only (Control group).
Number of subjects: 60
Study: 34496300

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52 mg intrauterine system (IUS) among women with heavy menstrual bleeding
Number of subjects: 6203

Group type: COMPARATOR
Intervention: Levonorgestrel 52 mg intrauterine system (IUS) among users for contraception (comparison group)
Number of subjects: 6203
Study: 34914334

Group type: EXPERIMENTAL
Intervention: Modified Shenqi Dihuang Decoction (MSDD) + Maximal Androgen Blockade (MAB)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Maximal Androgen Blockade (MAB)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: MSDD + MAB
Number of subjects: 76
Study: 34775656

Group type: EXPERIMENTAL
Intervention: Stroboscopic glasses during 4-week balance training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no stroboscopic glasses)
Number of subjects: 28
Study: 32414192

Group type: EXPERIMENTAL
Intervention: GENEActiv accelerometers worn on non-dominant and dominant wrists, ankles, and waist during physical activity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GENEActiv accelerometers worn on dominant wrist, waist, non-dominant and dominant ankles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GENEActiv accelerometers worn on non-dominant wrist
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cut-points validated in the calibration
Number of subjects: 20
Study: 36114901

Group type: EXPERIMENTAL
Intervention: Denosumab treatment
Number of subjects: 305
Study: 35297472

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention targeting physical weakness, cognitive impairment, malnutrition, and anemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual inpatient care
Number of subjects: 0
Study: 32080973

Group type: EXPERIMENTAL
Intervention: Vialon biomaterial catheter (BD Insyte™ Autoguard™ BC winged)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Teflon catheter (BD Venflon™)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Vialon biomaterial catheter
Number of subjects: 208

Group type: COMPARATOR
Intervention: Teflon catheter
Number of subjects: 208
Study: 36260832

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) + Reirradiation (re-RT) 35 Gy in 10 fractions with concurrent BEV IV 10 mg/kg every 2 weeks
Number of subjects: 182

Group type: COMPARATOR
Intervention: Bevacizumab (BEV) alone
Number of subjects: 182
Study: 34245667

Group type: EXPERIMENTAL
Intervention: Complete intra-ureteric stent (CIUS)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional ureteric JJ stent (CUS)
Number of subjects: 124
Study: 33917770

Group type: EXPERIMENTAL
Intervention: High-Load Resistance Exercise (HL-RE)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Low-Load Resistance Exercise (LL-RE)
Number of subjects: 43
Study: 33031736

Group type: EXPERIMENTAL
Intervention: Weight management intervention (n=64)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine diabetes management (Control group, n=26)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Weight management intervention (n=32 responders)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine diabetes management (Control group, n=13 non-responders)
Number of subjects: 90
Study: 35428035

Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation (CR)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 63
Study: 33499543

Group type: EXPERIMENTAL
Intervention: Military Treatment Facility Engagement Committee (MTFEC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain Management Collaboratory Coordinating Center (PMC3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engagement strategies
Number of subjects: 0
Study: 34081966

Group type: EXPERIMENTAL
Intervention: LCI+EAC
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: LCI
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: EAC
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard HD colonoscopy
Number of subjects: 1000
Study: 32278676

Group type: EXPERIMENTAL
Intervention: Baseline circulating tumor cell (bCTC) count ≥3
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: BRAF mutated tumors
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: RAS mutated tumors
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: PIK3CA mutated tumors
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: High microsatellite instability (MSI)
Number of subjects: 1202
Study: 35344464

Group type: EXPERIMENTAL
Intervention: sIPV (Sabin inactivated poliovirus vaccine)
Number of subjects: 300
Study: 34581737

Group type: EXPERIMENTAL
Intervention: Contact aspiration and stent retriever combined
Number of subjects: 405

Group type: COMPARATOR
Intervention: Stent retriever alone
Number of subjects: 405
Study: 32991589

Group type: EXPERIMENTAL
Intervention: Video intervention (n = 333)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Text intervention (n = 322)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Control group (n = 368)
Number of subjects: 1023
Study: 34605307

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 35
Study: 35244878

Group type: EXPERIMENTAL
Intervention: Mother-Newborn Care Unit (MNCU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional NICU
Number of subjects: 0
Study: 34203036

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Manual Massage (MM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cognitively oriented relaxation routine (Control)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR) and Manual Massage (MM)
Number of subjects: 65
Study: 36056417

Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 34965953

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon alpha (BEV+IFN)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Interferon alpha alone (IFN)
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment with IL-6 and HGF
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Model based on IL-6, HGF and bevacizumab treatment
Number of subjects: 732
Study: 36058418

Group type: EXPERIMENTAL
Intervention: Instructed positive interaction + intranasal oxytocin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control + intranasal oxytocin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Instructed positive interaction + placebo
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control + placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall group assignment
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: TNF-α responses to wounding
Number of subjects: 160
Study: 33159658

Group type: EXPERIMENTAL
Intervention: 0.5 mg semaglutide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.0 mg semaglutide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 32954593

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus erlotinib (RAM + ERL)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo plus erlotinib (PL + ERL)
Number of subjects: 336
Study: 34605142

Group type: EXPERIMENTAL
Intervention: Ultra-rapid lispro (URLi)
Number of subjects: 0
Study: 34531736

Group type: EXPERIMENTAL
Intervention: Oroxylum indicum extract (500 mg, twice daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (Oroxylum indicum and placebo)
Number of subjects: 82
Study: 32930550

Group type: EXPERIMENTAL
Intervention: Group A (activation letter)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Group B (activation letter + financial incentive)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Group C (activation letter + financial incentive + telephone call)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study: 34271945

Group type: EXPERIMENTAL
Intervention: OPEN ARCH intervention (duration of 3, 6, or 9 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (participants served as their own control)
Number of subjects: 80
Study: 33121454

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Conscious Sedation (CS)
Number of subjects: 187
Study: 34060903

Group type: EXPERIMENTAL
Intervention: Coarsened Exact Matching (CEM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propensity Score Matching (PSM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CEM and PSM
Number of subjects: 0
Study: 34918028

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV1) with TB treatment containing rifapentine (1200 mg), isoniazid, pyrazinamide, and either ethambutol or moxifloxacin
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV2) with TB treatment containing rifapentine (1200 mg), isoniazid, pyrazinamide, and either ethambutol or moxifloxacin
Number of subjects: 111
Study: 34887285

Group type: EXPERIMENTAL
Intervention: 5 mg of zoledronic acid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35973166

Group type: EXPERIMENTAL
Intervention: AI‐CNN model
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Routine practice (control group)
Number of subjects: 1434
Study: 34327851

Group type: EXPERIMENTAL
Intervention: Peanut consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate bars
Number of subjects: 0
Study: 34591982

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 2436

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 2436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2436

Group type: EXPERIMENTAL
Intervention: Postmarketing data
Number of subjects: 2436
Study: 36260385

Group type: EXPERIMENTAL
Intervention: Patient education via Instagram for 5 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 49
Study: 32472610

Group type: EXPERIMENTAL
Intervention: Gains in 7p22 (8.5%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gains of 11q (CCND1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Deletions of 17p (TP53) and 9p (CDKN2A)
Number of subjects: 100
Study: 35315830

Group type: EXPERIMENTAL
Intervention: Arch-support insoles
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flat insoles
Number of subjects: 20
Study: 34661664

Group type: COMPARATOR
Intervention: High-dose deutetrabenazine (up to 48 mg/d)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Low-dose deutetrabenazine (up to 36 mg/d)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 158

Group type: COMPARATOR
Intervention: High-dose deutetrabenazine
Number of subjects: 158

Group type: COMPARATOR
Intervention: Low-dose deutetrabenazine
Number of subjects: 158
Study: 35156511

Group type: EXPERIMENTAL
Intervention: Structured postoperative rehabilitation
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard postoperative approach
Number of subjects: 149
Study: 34418139

Group type: EXPERIMENTAL
Intervention: ROLE‐AP programme over a 3‐week period
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal routine (Control)
Number of subjects: 30
Study: 34391242

Group type: EXPERIMENTAL
Intervention: Fascial therapy, strength training, and kinesiotaping
Number of subjects: 36

Group type: COMPARATOR
Intervention: Myofascial techniques and eccentric training (control)
Number of subjects: 36
Study: 33247774

Group type: EXPERIMENTAL
Intervention: Bacterial Cellulose (BC) dressing
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vaseline with gauze
Number of subjects: 26
Study: 35936372

Group type: EXPERIMENTAL
Intervention: Preoperative psychological nursing intervention combined with traditional preoperative education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional preoperative education
Number of subjects: 60
Study: 32778992

Group type: EXPERIMENTAL
Intervention: Combined (ADHD + tobacco) intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: ADHD only intervention
Number of subjects: 63
Study: 36450422

Group type: EXPERIMENTAL
Intervention: Continue RAS inhibiting therapy
Number of subjects: 215

Group type: COMPARATOR
Intervention: Discontinue RAS inhibiting therapy
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Continue RAS inhibiting therapy (mechanistic substudy)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Discontinue RAS inhibiting therapy (mechanistic substudy)
Number of subjects: 215
Study: 33386890

Group type: EXPERIMENTAL
Intervention: Grape powder (46 g, equivalent to 252 g fresh grapes)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 32253602

Group type: EXPERIMENTAL
Intervention: Cancer survivors (CS)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Cancer-free controls
Number of subjects: 263
Study: 32894871

Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Immediate Cord Clamping (ICC)
Number of subjects: 56
Study: 33246495

Group type: EXPERIMENTAL
Intervention: Multi-faceted community and clinic-based strategies including expanded community health worker services, home BP self-monitoring, and a storytelling intervention delivered via DVDs at baseline and at 3, 6, and 9 months.
Number of subjects: 680

Group type: COMPARATOR
Intervention: Multi-level intervention modeled after the Vietnam National Hypertension Program including education and practice change modules for health care providers, accessible reading materials for patients, and a multi-media community awareness program.
Number of subjects: 680
Study: 35779491

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine
Number of subjects: 15169

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 15169
Study: 34480873

Group type: EXPERIMENTAL
Intervention: Midurethral sling
Number of subjects: 324

Group type: COMPARATOR
Intervention: Sham incisions
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Midurethral sling and Sham incisions
Number of subjects: 324
Study: 35962939

Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg (every 8 weeks)
Number of subjects: 2025

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg (every 8 weeks)
Number of subjects: 2025

Group type: COMPARATOR
Intervention: Tramadol (100–300 mg/day)
Number of subjects: 2025

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2025
Study: 32591267

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine preconception care
Number of subjects: 70
Study: 36433716

Group type: EXPERIMENTAL
Intervention: Core Stabilisation (CS) Group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Auxiliary Respiratory Muscles Exercise (ARM) Group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (C) Group
Number of subjects: 51
Study: 34491803

Group type: EXPERIMENTAL
Intervention: SPR720 (100 to 2000 mg single doses or 500 to 1500 mg daily doses for 7 or 14 days)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: SPR720
Number of subjects: 96
Study: 32304881

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 80
Study: 35338430

Group type: EXPERIMENTAL
Intervention: Jiao-Tai-Wan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 50
Study: 32744369

Group type: EXPERIMENTAL
Intervention: 0.01% bimatoprost ophthalmic solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.1% tacrolimus ointment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups (bimatoprost and tacrolimus)
Number of subjects: 10
Study: 34728124

Group type: EXPERIMENTAL
Intervention: EBNPG knowledge training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EBNPG knowledge training plus an implementation toolkit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 32896775

Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/day
Number of subjects: 0
Study: 33933738

Group type: EXPERIMENTAL
Intervention: Increased serum calcium levels (per 0.5 mg/dL)
Number of subjects: 61079
Study: 36444676

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Self-help group
Number of subjects: 280
Study: 32737900

Group type: EXPERIMENTAL
Intervention: Nitric oxide at a dose of 20 ppm added to the sweep gas during CPB
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (sweep gas without nitric oxide)
Number of subjects: 40
Study: 34399427

Group type: EXPERIMENTAL
Intervention: Oxygen-enriched air (40% O2)
Number of subjects: 10
Study: 33611164

Group type: EXPERIMENTAL
Intervention: Metronomic oral vinorelbine (mVNR) at a fixed dose of 50 mg × 3
Number of subjects: 167

Group type: COMPARATOR
Intervention: Standard schedule of vinorelbine (60-80 mg/m2 weekly)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Metronomic oral vinorelbine (mVNR)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Standard schedule of vinorelbine
Number of subjects: 167
Study: 32378956

Group type: EXPERIMENTAL
Intervention: Stress reappraisal
Number of subjects: 266

Group type: COMPARATOR
Intervention: Emotional suppression
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control (no instructions)
Number of subjects: 266
Study: 36461128

Group type: EXPERIMENTAL
Intervention: Group psychoeducation program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting list arm (Control)
Number of subjects: 50
Study: 34271465

Group type: EXPERIMENTAL
Intervention: Palisade grass (Urochloa brizantha cv. Marandu)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Eucalypt (Eucalyptus urophylla x Eucalyptus grandis)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Indian mustard (Brassica juncea L.)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No plant control
Number of subjects: 3
Study: 36223056

Group type: EXPERIMENTAL
Intervention: 3 monthly injections of intravitreal ranibizumab (IVR) + pro re nata (PRN) dosing
Number of subjects: 74

Group type: COMPARATOR
Intervention: 1 initial injection of intravitreal ranibizumab (IVR) + pro re nata (PRN) dosing
Number of subjects: 74
Study: 33377600

Group type: EXPERIMENTAL
Intervention: Experimental group with task-state fMRI results
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group with hollowing and multiple subpial transection operation only
Number of subjects: 34
Study: 35149535

Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 3341

Group type: COMPARATOR
Intervention: Non-HPV vaccination (control)
Number of subjects: 3341
Study: 32891527

Group type: EXPERIMENTAL
Intervention: Activity monitor with virtual activity groups
Number of subjects: 120

Group type: COMPARATOR
Intervention: Activity monitor without virtual activity groups
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 32522420

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HLA)-based vaginal gel, used daily for the first 2 weeks, then 3 times/week until weeks 12-14, increased to 5 times/week for non-responders.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HLA)-based vaginal gel
Number of subjects: 43
Study: 34015342

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 7.5 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 15 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 30 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 34213494

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg intravenous injection)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg intravenous injection)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 μg/kg intravenous injection)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study: 35526835

Group type: COMPARATOR
Intervention: IHC 0+ without staining
Number of subjects: 0

Group type: COMPARATOR
Intervention: IHC 0+ with some staining
Number of subjects: 0

Group type: COMPARATOR
Intervention: IHC 1+
Number of subjects: 0
Study: 32847382

Group type: EXPERIMENTAL
Intervention: Panna wire
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional wire
Number of subjects: 100